Last reviewed · How we verify
NCT06017622
Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression
trial in Acute Cannabis-induced CNS Depression in 36 participants. Currently enrolling.
30 December 2026
Quick facts
| Lead sponsor | Anebulo Pharmaceuticals |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 36 |
| Start date | 1 June 2023 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across United States |
Conditions studied
- Acute Cannabis-induced CNS Depression — all drugs for Acute Cannabis-induced CNS Depression →
Sponsor
Anebulo Pharmaceuticals — full company profile →
Who can join
Eligibility, any sex, with Acute Cannabis-induced CNS Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of pediatric patients who visit the emergency department due to acute cannabis-induced CNS depression.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06017622
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Anebulo Pharmaceuticals trials
Trials by the same sponsor.
- NCT07211607 — I.V. Selonabant in Healthy Adult Subjects · Phase 1 · recruiting
- NCT05282797 — Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06017622 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anebulo Pharmaceuticals
- Last refreshed: 17 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06017622.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing